Shares of biotech company Biogen were moving higher on Thursday after the company received an upgrade from an analyst. RBC Capital Markets analyst Brian Abrahams upgraded Biogen stock on hopes for its Alzheimer’s drugs. Abrahams sees an $8 billion peak opportunity if the CMS decision comes out in Aduhelm’s favor and if Biogen succeeds with … Continue reading “Biogen Gets Analyst Upgrade and Announces Layoffs”
Tag: biogen
Biogen Shares Fall as Medicare Proposal Restricts Alzheimer’s Treatment Coverage
Shares of Biogen were falling this week after the U.S. Medicare program's proposal to severely…
Biogen Shares Explode on Talks that Company is to be Bought by Samsung
In a deal valued at potentially over $40 billion, rumors surfaced that Biogen may be…
Biogen Shares Explode on FDA Approval of Alzheimer’s Drug
Shares of biotech company Biogen were soaring on Monday after Wall Street learned that the…
Biogen Tumbles After Delay of Alzheimer’s Treatment Submission
Shares of biotech giant Biogen were falling on Wednesday after the company said it would…
Canaccord Analyst Gives “Buy” Rating on Biogen Despite Skepticism on Its Alzheimer’s Drug Getting Approved
Cannacord Genuity analyst Sumant Kulkarni has upgraded shares of Biogen Inc. from "hold" to "buy"…
Biogen Surprises Wall Street With This News
Biogen announced on Tuesday that its Alzheimer's treatment was ready to start the regulatory approval…
Biogen Shares Explode on Positive Results from Alzheimer’s Drug Trial
Shares of Biogen were climbing higher on Friday after the company and Eisai announced the…
Biogen (BIIB) Gets Upgrade Because Of This Blockbuster Drug
Biogen shares were upgraded from hold to buy by Citi Research on Tuesday. The firm…
Biogen (BIIB) Shares Explode After WallStreet Report
A report by the Wall Street Journal, indicating that Merck & Co. and Allergan Plc…
Ionis Pharmaceuticals (IONS) Achieves Major Milestone
Ionis shares saw a big pop in pre market trading on Monday, rising 37% to…